Determination of efficacy, Adverse drug reactions and cost effectiveness of three triple drug regimens for the treatment of Helicobacter pylori infected acid peptic disease patients

Asian Pacific Journal of Tropical Disease

Volumn 2, Issue SUPPL2, 2012, Pages

  Ghosh, Pinaki ^a   Kandhare, Amit D ^a   Gauba, Divya ^a   Raygude, Kiran S ^a   Bodhankar, Subhash L ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Helicobacter pylori; Pharmacoeconomics; Side effect

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; GENOMIC DNA; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RNA 16S; TINIDAZOLE;

ABDOMINAL PAIN; ABNORMAL FECES; ARTICLE; BACTERIAL GENE; CAG T GENE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPEPSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PEPTIC ULCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; TASTE DISORDER; TREATMENT OUTCOME;

EID: 84871727044     PISSN: 22221808     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2222-1808(12)60265-5     Document Type: Article

References (53)

1. Hagymasi K, Tulassay Z Peptic ulcer: facts and questions-2010. Orv Hetil 2010, 151(26):1054-1061.
2. Kandhare AD, Raygude KS, Ghosh P, Bodhankar SL The ameliorative effect of fisetin, a bioflavonoid, on ethanol-induced and pylorus ligation-induced gastric ulcer in rats. Int J Green Pharm 2011, 5:236-243.
3. Ghosh P, Kandhare AD, Raygude KS, Gauba D, Gosavi TP, Bodhankar SL Cigarette smoking and H. pylori infection: A meta-analysis of literature. Der Pharmacia Lettre 2012, 4(1):128-134.
4. Sung JJ Marshall and warren lecture 2009: peptic ulcer bleeding: an expedition of 20 years from 1989-2009. J Gastroenterol Hepatol 2010, 25(2):229-233.
5. Gosavi TP, Ghosh P, Kandhare AD, Bodhankar SL Therapeutic effect of H. pylori nosode in healing of chronic H. pylori infected ulcers in laboratory animals. Asian Pac J Trop Dis 2012, In press. D152.
6. Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL Patentability of Animal Models: India and the Globe. Int J Pharm Biol Arc 2011, 2(4):1024-1032.
7. Raygude KS, Kandhare AD, Ghosh P, Gosavi TP, Bodhankar SL Consumption of Alcohol and H. pylori infection: A Cumulative Meta-Analysis of Literature. Asian J Biochem Pharm Res 2011, 3(1):338-345.
8. Ahmed KS, Khan AA, Ahmed I, Tiwari SK, Habeeb A, Ahi JD, et al. Impact of household hygiene and water source on the prevalence and transmission of Helicobacter pylori: a South Indian perspective. Singapore Med J 2007, 48(6):543-549.
9. Ghosh P, Bodhankar SL Application of polymerase chain reaction for determination of prevalence of Helicobacter pylori in salivary samples of asymptomatic subjects. Asian J Pharm Clin Res 2011, 4(3):21-24.
10. Ghosh P, Bodhankar SL Association of Smoking, alcohol and NSAID use with expression of cag A and cagT genes of H. pylori in salivary samples of asymptomatic subjects. Asian Pac J Trop Biomed 2012, 1(1):479-484.
11. Ghosh P, Bodhankar SL Determination of risk factors and transmission pathways of Helicobacter pylori in asymptomatic subjects in western India using polymerase chain reaction A. Sian Pac J Trop Dis 2012, 1(1):12-17.
12. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999, 13(7):857-864.
13. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998, 12(4):383-388.
14. Calvet X, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, Guirao R One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Group for Eradication Studies from Catalonia and Aragón (Gresca). Aliment Pharmacol Ther 2002, 16(7):1261-1267.
15. Gosavi TP, Ghosh P, Kandhare AD, Bodhankar SL Unwrapping Homeopathic Principles in the Wake of Research: Serendipity, Placebo or True Therapeutic Milestones. Pharmacologyonline 2011, 1:894-906.
16. Ayyagarii A, Sharma S, Prasad KN, Yalha SK, Naik SR. Metronidazole Resistant H. pylori in India. Proceedings of 10th World Congress of Gastroenterology, USA. 1994: p 97.
17. Balamourougane BP, Kundargi VS, Kate V, Ananthakrishnan N Drug therapy for H. pylori - are nitroimidazoles useful in indian patients?. Indian J Pharmacol 2002, 34:111-114.
18. Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL A comparative cross sectional descriptive study of individual pharmacy Vs mall pharmacies to evaluate customer satisfaction as well as purchasing behavior. Der Pharmacia Lettre 2011, 3(4):71-83.
19. Patil MVK, Kandhare AD, Bhise SD Evaluation of patient information leaflets on basis of consumer psychology and opinion. Int J Phar Pharm Sci Res 2011, 1(2):87-92.
20. Gosavi TP, Kandhare AD, Raygude KS, Ghosh P, Bodhankar SL A comparative study on the efficacy, safety and cost effectiveness of Viscum album and Rauwolfia serpentina mother tincture in hypertensive patients. Deccan J. Natural Products 2011, 2(3):29-35.
21. Patil MVK, Kandhare AD, Bhise SD, Bhale S A comparative cross sectional descriptive market survey of various brands of Levofloxacin. Asian J Pharm Biol Res 2011, 1(2):174-181.
22. Navazesh M Methods for collecting saliva. Ann NY Acad Sci 1993, 694:72-77.
23. Tiwari SK, Khan AA, Khan SA, Ali M, Habeeb MA, Kauser F, et al. PCR based analysis of the cag-PAI of Helicobacter pylori from saliva: An approach for rapid molecular genotyping in correlation with disease status. J Gastroentero Hepatol 2005, 20(10):1560-1568.
24. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Bodhankar SL Therapeutic role of curcumin in prevention of biochemical and behavioral aberration induced by alcoholic neuropathy in laboratory animals. Neurosci Lett 2012, 511:18-22.
25. Raygude KS, Kandhare AD, Ghosh P, Ghule AE, Bodhankar SL Evaluation of ameliorative effect of quercetin in experimental model of alcoholic neuropathy in rats. Inflammopharmacol 2012, 10.1007/s10787-012-0122-z.
26. Gosavi TP, Kandhare AD, Raygude KS, Ghosh P, Bodhankar SL Evaluation of clinical outcome in arthritis with AIMS2. Deccan J Pharmacol 2011, 2(3):10-30.
27. Ghosh P, Kandhare AD, Shiva Kumar V., Rajmane AR, Mohammad Adil, Bodhankar SL Determination of clinical outcome and pharmacoeconomics of anti-rheumatoid arthritis therapy using CDAI, EQ-5D-3L and EQ-VAS as indices of disease amelioration. Asian Pac J Trop Dis 2012, In press. D157.
28. Shini VK, Aboobacker S, Pahuja S, Revikumar KG, Bhasi R Pharmacoeconomic study of DMARDs in the management of rheumatoid arthritis. Inter J Pharm Sci Rev Res 2010, 5(3):148-154.
29. Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmülling C, Neugebauer E, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995, 82(2):216-222.
30. Timshina DK, Pankaja SS, K Rao HK, Kate V. Evaluation of Helicobacter pylori infection and other risk factors in patients with benign peptic ulcer disease. Asian Pac J Trop Dis 201; 1(1): 50-51.
31. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Gosavi TP, Badole SL, Bodhankar SL Effect of hydroalcoholic extract of Hibiscus rosa sinensis Linn. leaves in experimental colitis in rats. Asian Pac J Trop Biomed 2012, 5:337-344.
32. Sasidharan S, Ghayethry B, Ravichandran M, Latha LY, Lachumy SJ, Leng KM, et al. Prevalence of Helicobacter pylori infection among patients referred for endoscopy: gender and ethnic differences in Kedah, Malaysia. Asian Pac J Trop Biomed 2012, 2(1):1-5.
33. Patil MVK, Kandhare AD, Bhise SD Anti-inflammatory effect of Daucus carota root on experimental colitis in rats. Int J Pharm Pharm Sci 2012, 4(1):337-343.
34. Patil MVK, Kandhare AD, Bhise SD Effect of aqueous extract of Cucumis sativus Linn. fruit in ulcerative colitis in laboratory animals. Asian Pac J Trop Biomed 2012, In press. 774.
35. Nash C, Fischbach L, Veldhuyzen Van Zanten S What are the global response rates to Helicobacter pylori eradication therapy?. Can J Gastroenterol 2003, 17(Suppl. B):25B-29B.
36. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56(6):772-781.
37. Miura S, Hokari RJ Seeking an optimal eradication therapy for Helicobacter pylori infection. Gastroenterol Hepatol 2012, 27(1):7-9. 10.1111/j.1440-1746.2011.06953.x.
38. Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011, 16(4):289-294.
39. Rimbara E, Fischbach LA, Graham DY Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011, 8(2):79-88.
40. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010, 15(3):233-238.
41. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011, 34(9):1098-1105.
42. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009, 104(12):3069-3079.
43. Moayyedi P, Malfertheiner P Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?. Am J Gastroenterol 2009, 104(12):3081-3083.
44. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010, 8(1):36-41.
45. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011, 378(9790):507-514.
46. Albrecht P, Kotowska M, Szajewska H Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial. J Pediatr 2011, 159(1):45-49.
47. Bontems P, Kalach N, Oderda G, Salame A, Muyshont L, Miendje DY, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011, 53(6):646-650.
48. Jodlowski TZ, Lam S, Ashby CR Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother 2008, 42(11):1621-1639.
49. Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 2011, 26(9):1457-1461.
50. Ching SS, Sabanathan S, Jenkinson LR Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol 2008, 14(24):3855-3860.
51. Mirsattari D, Zojaji H, Mahboubi H, Molaei M, Derakhshan F, Zali M Quadruple versus common triple-treatment regimens for Helicobacter pylori eradication in the Iranian population: A randomised study. Arab J of Gastroenterol 2010, 11:187-191.
52. El-Mekki A, Kumar A, Alknawy B, Al-Ammari O, Moosa R, Quli S, Ahmed M Comparison of enzyme immunoassays detecting Helicobacter pylori specific IgG in serum and saliva with endoscopic and biopsy findings in patients with dyspepsia. Indian. J Med Microbiol 2011, 29(2):136-140.
53. Tiwari SK, Khan AA, Manoj G, Ahmed S, Abid Z, Habeeb A, et al. A simple multiplex PCR assay for diagnosing virulent Helicobacter pylori infection in human gastric biopsy specimens from subjects with gastric carcinoma and other gastro-duodenal diseases. J Appl Microbiol 2007, 103(6):2353-2360.